Peroxisome proliferator-activated receptor alpha (PPAR ) regulates transcription of genes involved both in lipid and glucose metabolism as well as in inflammation. Fibrates are PPAR ligands used to normalize lipid and glucose parameters and exert antiinflammatory effects. In fact, fibrates have already been demonstrated to benefit metabolic syndrome, type 2 diabetes and cardiovascular diseases. This article reviews the mechanism of action and the functional roles of fibrates, emphasizing the factors modulating their capacity to activate PPAR and affecting their effectiveness. These factors may possibly explain the findings obtained in animal studies and clinical trials with fibrates which showed either untoward effects and/or inefficient hypolipidemic action of PPAR activation. We also discuss briefly the natural and synthetic agonists of PPAR which are currently being developed and supposedly display greater effectiveness and fewer adverse effects than fibrates.
acids efficiently bind PPAR [5] . Thus, eicosanoids derived from arachidonic acid via lipoxygenase pathway, leukotrienes and oxidized fatty acids, all involved in inflammatory processes, are also natural ligands for PPAR [5] . Synthetic ligands: PPARs are also activated by peroxisome proliferators, a large class of structurally diverse compounds that include hypolipidemic drugs, plasticizers, herbicides and solvents. These hypolipidemic agents are fibrates such as clofibrate, fenofibrate, bezafibrate, gemfibrozil and, an experimental compound, Wy-14,643. Other synthetic compounds that bind to PPAR include the 5,8,11,14 eicosatetraynoic acid, an arachidonic acid analog [5] , and non-steroidal antiinflammatory drugs, which also appear to activate PPAR [6] . Fibrates preferentially bind PPAR [2] , whereas thiazolidinediones (TZDs) are a class of antidiabetic drugs which selectively bind PPAR [7] . It also seems that retinoid X receptor (RXR) (NR2B) agonists, such as the natural ligand 9-cis retinoic acid, can induce PPAR:RXR heterodimers and activate PPAR target genes [8] .
MECHANISM OF ACTION AND FUNCTIONAL ROLES
The biological and therapeutic activities of PPAR are the result of the combination of two distinct mechanisms ( Fig.  (1) ): i) one ligand-dependent transactivation controls metabolic effects, and ii) ligand-dependent transrepression, which controls vascular effects. Since the present article is concerned with fibrates, which mainly act on PPAR , we will focus on the mechanism of action of this PPAR subtype.
TRANSCRIPTIONAL ACTIVATION
The typical function of PPAR is to activate transcription in a ligand-dependent manner, following direct binding to DNA response elements in the promoter or enhancer regions of target genes. Transcriptional regulation by PPARs requires heterodimerization with RXR, which belongs to the same receptor superfamily. The PPAR:RXR complex, acti-vated by ligand, modulates transcription via binding to a specific DNA sequence element, peroxisome proliferator response element or PPRE. This response element is generally composed of two half-sites that occur as a direct repetition of the consensus sequence AGGTCA with a single nucleotide spacing between the two repeats. Hence, it is named DR-1. Nevertheless, the ability of nuclear receptors to initiate or suppress the transcription process relies on their interaction with negatively or positively acting cofactors. These cofactors serve as a bridge between transcription factors and the basic transcription machinery (Fig. (1A) ) and, more importantly, contain several enzymatic activities controlling gene expression by specifically modifying chromatin and DNA structure. Acetylation of hystones is one critical regulatory mechanism by which gene expression is regulated. In general, increased levels of histone acetylation loosen chromatine packaging and have been correlated with transcriptional activation, whereas decreased activity of histone acetylase is associated with transcriptional repression [9] . In the absence of a ligand, PPAR:RXR heterodimers associates with corepressors, containing histone deacetylase activity [10] . The deacetyled state of histone inhibits transcription [11] . On the other hand, ligand binding induces conformational change in the PPAR, resulting in the release of corepressors and recruitment of coactivators. Some coactivators present histone acetylase activity [11] . Interaction of nuclear receptors with these coactivators results in the binding of the heterodimer to PPRE in the promoter, modification of the chromatine structure and either the activation or supression of the transcription of the target gene. This model implies that chromatine is flexible enough to allow looping ( Fig. (1A) ).
GENE REPRESSION
PPAR can also negatively regulate gene expression in a ligand-dependent manner by inhibiting the activities of other transcription factors (Fig. (1B) ), such as members of nuclear factor-kappa B (NF-B), activator protein-1 (AP-1) families [12, 13] , signal transducer and activator of transcription (STAT), CCAAT/enhancer binding protein (C/EBP) [14] , hepatocyte nuclear factor 4 alpha (HNF4 ) and others [15] . This mechanism does not involve binding to typical receptor specific response elements in the DNA molecule. However, despite the large number of studies carried out, the mechanisms by which PPARs inhibit these signal transduction pathways are not completely understood. Ricote et al. [16] have recently reviewed the molecular mechanisms that may account for gene-specific transrepression by PPAR ligands: direct protein-protein interactions between PPAR and other transcription factors; modulation of kinase activity; competition for the coactivators; and the corepressor-dependent model. Moreover, one of these models of transrepression has established that PPAR upregulates expression of the NF-kB repressor, inhibitor of kappa B (I B), which sequesters the NF-B subunits and prevents their translocation to the nucleus and, consequently, their DNA binding activity [17] . Thus, PPAR can inhibit genes induced by NF-kB. On the other hand, the interference of PPAR with the C/EBP and HNF4 signalling pathways can be explained, as PPAR decreases the expression of HNF4 [18] as well as that of C/EBP [19] . that whereas fibrates and fatty acids clearly induce LPL mRNA in liver ( Fig. (2) ), contradictory results have been found in adipose and other extrahepatic tissues [15, 20, 21] . Thus, the effect of PPAR agonists on plasma TG-rich lipoprotein removal seems to be mainly due to changes in the hepatic expression of inhibitors (apolipoprotein (apo) C-III) and activators (apo A-V) of LPL activity ( Fig. (2) ) [15] . In fact, apo C-III levels appear to correlate positively with plasma TG concentrations. On the other hand, the recently discovered apo A-V has been shown to play an important role in determining TG levels in humans and mice, and represents the first described apolipoprotein gene in which overexpression lowers TG levels. Thus, PPAR activators enhance the catabolism of VLDL, which results in changes in low density lipoprotein (LDL) composition, increasing its removal by the tissues.
Effects in VLDL Production
Any process that may limit the liver availability of fatty acids for conversion to TG will affect VLDL production. First of all, cellular uptake of long-chain fatty acids is facili-tated and regulated by fatty acid transporters, such as the fatty acid transporter protein (FATP) and the fatty acid translocase (FAT), also called CD36. The expression of both fatty acid transporters in rat liver is enhanced by fibrates or fatty acids ( Fig. (2) ) [22] . The conversion of free fatty acids (FFA) to acyl-CoA derivatives by acyl-CoA synthetase (ACS) prevents efflux from the cell, and activates FFA for utilization in both catabolic and/or anabolic pathways. ACS gene expression and activity are induced by fibrates and fatty acids in a variety of tissues and cells ( Fig. (2) ) [23] . Once in the cytoplasm, FFA bind to transport proteins, such as the fatty acid binding protein (FABP) and acyl-CoA binding protein (ACBP). Hypolipidemic drugs are also able to induce expression of FABP via PPAR ( Fig. (2) ) [24] .
A process that may limit the fatty acid availability for conversion to TG and subsequent conversion as VLDL is fatty acid catabolism [15] . The critical role of PPAR agonists in the regulation of oxidation of fatty acids has been well documented. As already commented, peroxisome proliferation was one of the first effects described in rodents after exposure to synthetic PPAR activators, and it has been related to an increase of the peroxisomal fatty acidoxidation activity [25] . This pathway is responsible for the metabolism of long-chain fatty acids and sequentially involves the enzymes acyl-CoA oxidase (ACO), enoyl-CoA hydratase/3-hydroxyacyl-CoA dehydrogenase (or L-bifunctional enzyme, HD) and 3-ketoacyl-CoA thiolase [26] . The L-and D-hydroxy intermediates, generated by the first step of the oxidation, can be metabolized by either HD protein or D-bifunctional protein (Hsd17b4) [27] . The activities of all these enzymes are stimulated in response to PPAR agonists, due to changes in the transcription rates of their genes ( Fig. (2) ) [28] . Thus, for example, Corton et al. [29] showed that Hsd17b4 expression was augmented by peroxisome proliferators in rodents. Moreover, trypsin domain containing 1 (Tysnd1) is a protease whose expression is induced by the PPAR agonist bezafibrate. Recently, Kurochkin et al. [30] have proposed a model suggesting that Tysnd1 mediates the processing of the peroxisomal enzymes (ACO, Hsd17b4, and thiolase) which promotes their assembly into a supramolecular complex to enhance the rate of -oxidation.
Nevertheless, fatty acid metabolism is mainly focused on its mitochondrial oxidation. The first limiting step in mitochondrial oxidation is the entry flux of fatty acids into the mitochondria. Carnitine palmitoyl transferase I (CPT-I) catalyzes the formation of fatty acyl-carnitine for translocation across the inner mitochondrial membrane. The CPT-I gene expression is upregulated by fatty acids and peroxisome proliferators ( Fig. (2) ) [25] . PPAR further regulates the mitochondrial oxidative spiral by modulating the expression of the medium-chain acyl-CoA dehydrogenase (MCAD) gene ( Fig. (2) ) [31] . Mitochondrial oxidation greatly contributes to energy production via oxidative phosphorylation generating ATP. However, PPAR appears to increase energy expenditure by inducing the expression of uncoupling proteins (UCPs) ( Fig. (2) ) [32] , such as UCP1, UCP2 and UCP3, mitochondrial transporters localized in the inner mitochondrial membrane that act to dissipate the proton gradient and increase thermogenesis while reducing the efficiency of ATP synthesis. On the other hand, the cytochrome monooxygenase system plays a central role in the oxidation of a wide variety of endogenous as well as exogenous compounds. The microsomal CYP4A enzymes participate in the system as a distinct group of the cytochrome P450 superfamily. They catalyze the hydroxylation of fatty acids and eicosanoids, such as leukotriene LTB4. In fact, hydroxylation is the first step in the neutralization of LTB4, which is then completely degraded through oxidation in the peroxisomes [25] . At least two of the CYP4A genes, CYP4A1 and CYP4A6, respond both in vivo and in cell culture to PPAR activators ( Fig. (2) ) [33, 34] .
Finally, PPAR is also involved in fatty acid synthesis. It has been shown that the lipogenic malic enzyme (ME) gene is upregulated by peroxisome proliferators via PPAR ( Fig.  (2) ) [35] . The reaction catalyzed by the ME consists of the oxidative decarboxylation of cytosolic malate, which generates pyruvate and leads to the formation of NADPH, which is required for lipid synthesis. With regard to the expression of genes more directly involved in TG synthesis, PPAR has recently been described as stimulating diacylglycerol acyltransferase (DGAT) gene expression ( Fig. (2) ) [15] . How-ever, PPAR agonists have been shown to increase DGAT activity in cytoplasm and to decrease it in endoplasmic reticulum, possibly diverting TG from incorporation into VLDL to the accumulation in cytosolic droplets [15] .
Effects in High Density Lipoprotein (HDL) Catabolism
PPAR appears to be the major isoform implicated in HDL metabolism [15] . Fibrates affect the expression of the enzymes and receptors regulating HDL metabolism. In rats, fibrates decrease the production of HDL-remodelling enzymes, such as hepatic lipase (HL) and lecithin:cholesterol acyltransferase (LCAT) ( Fig. (2) ) [36, 37] . Murine scavenger receptor I (SR-BI) and its human homologue CLA-I have been identified as HDL receptors which bind HDL with high affinity. They mediate the selective uptake of cholesteryl esters by liver and steroidogenic tissues [38, 39] , and may also promote cholesterol removal from peripheral cells, including macrophages. Treatment of human macrophages with PPAR activators resulted in the induction of CLA-I expression, suggesting that PPAR promotes cholesterol efflux to HDL in macrophages [15] . Furthermore, SR-BI is induced in aortas of apo E deficient mice when treated with a PPAR agonist. On the contrary, fibrates through PPAR reduce SR-BI gene expression in rodent liver ( Fig. (2) ) [15] .
EFFECTS IN GLUCOSE METABOLISM
PPARs also play an important role in glucose homeostasis. In fact, PPAR agonists, by up-regulating fatty acid oxidation and ketone body production, are able to spare glucose. Accordingly, PPAR null mice present hypoglycemia during starvation due to a diminished capability to oxidize fatty acids and a reduced capacity for hepatic gluconeogenesis [40] . Furthermore, several studies have indicated a beneficial effect of PPAR activation on insulin sensitivity [41, 42] . Thus, hyperinsulinemia and hyperglycemia observed in both mice subjected to a high-fat diet and genetic insulin resistant rodents [41] , were sharply lowered by treatment with fibrates.
More specifically, the glycolitic enzyme, liver-type pyruvate kinase (L-PK) plays a key role in hepatic glucose and lipid metabolism. L-PK gene transcription is inhibited by PUFA 3 and activators of PPAR ( Fig. (2) ). Moreover, PUFA and Wy-14,643 interfere, although by different mechanisms, with glucose-stimulated pyruvate kinase gene transcription both in vivo and in rat primary hepatocytes [43] . On the other hand, pyruvate dehydrogenase catalyzes the transformation of pyruvate into acetyl-CoA, and therefore controls both the transformation of pyruvate to different metabolic compounds such as fatty acid or amino acids, and its complete oxidation. The pyruvate dehydrogenase kinase 4 (PDK4) inactivates the pyruvate dehydrogenase complex via phosphorylation, thus guiding the utilization of pyruvate to gluconeogenesis rather than its oxidation to acetyl-CoA. PPAR exerts a direct role in the regulation of gluconeogenesis via stimulation of the expression of PDK4 ( Fig. (2) ) [44] . In fasted PPAR null mice, glucose synthesis from lactate is strongly reduced, demonstrating that PPAR also influences substrate utilization for glucose production in the liver [45] . However, hepatic glucose production was surprisingly higher in the PPAR null mice than in the wild type animals at the end of a fasting period, due to increased glucose production from glycerol in these animals [45] . These data reveal that the severe hypoglycemia observed in the PPAR null mice during fasting is not due to reduced glucose production but to increased glucose disposal [46] . Another enzyme of the glucose biosynthesis pathway regulated by PPAR is phosphoenolpyruvate carboxykinase (PEPCK), which catalyzes a rate-limiting step in gluconeogenesis. However, there are conflicting results regarding the consideration of PEPCK as a PPAR target gene in liver ( Fig. (2) ) [47] , since expression of the PEPCK gene is stimulated by a fasted state in both wild-type and PPAR -null mice [40] . PEPCK gene expression is responsive to fatty acids in adipocytes but not in hepatocytes [48] .
As regards insulin-sensitizing effects, genetic ablation of PPAR has no effect on insulin sensitivity [49] . Thus, PPAR null mice on normal chow did not demonstrate signs of insulin resistance in spite of having markedly increased circulating fatty acids and TG [50] . Moreover, PPAR null mice have also been shown to be protected from developing insulin resistance when on a high-fat diet or more simply, during ageing [49] . On the other hand, other authors, using a hyperinsulinemic-euglycemic clamp, have proposed that PPAR deficiency does not protect against high-fat dietinduced insulin resistance [50] . Curiously, Knauf et al. [51] activated brain PPAR in wild-type mice by infusing Wy-14,643 into the lateral ventricle and showed that whole-body glucose use was reduced. These same authors reexpresssed PPAR in the liver of knockout mice using recombinant adenoviruses, however, the whole-body glucose use rate remained elevated [51] . These findings would suggest that, although PPAR is involved in the regulation of insulin sensitivity, it is done by mechanisms that do not require PPAR expression in the liver.
EFFECTS IN VASCULAR AND HEPATIC INFLAM-MATION
The role of inflammation in atherosclerosis is well established [14] . The vascular lesions of atherosclerosis are not only the result of lipid accumulation but also the result of vascular injury leading to activation of specific cellular and molecular responses in the vascular wall and the immune system. PPAR controls vascular biology, including cell recruitment and activation, the local inflammatory response, vascular constriction and cell migration and thrombosis [4, 14] . PPAR inhibits genes of inflammatory markers induced by NF-B ( Fig. (1B) ), such as vascular cell-adhesion molecule-1 (VCAM-1), cyclooxygenase-2 (COX-2) and interleukins (IL-6 and IL-1), providing a molecular basis for the antiinflammatory effect of PPAR ligands in vivo. Moreover, similar to synthetic PPAR agonists, LPL-treated VLDL represses cytokine-induced VCAM-1 expression in wild-type but not in PPAR -deficient endothelial cells (ECs) [52] . PPAR also inhibits the production of endothelin-1 (ET-1) and tissue factor (TF) in ECs, vascular smooth muscle cells (VSMCs) and macrophages [13, 53] , and increases the expression of endothelial nitric oxide synthase (eNOS) in vascular cells [54] . All these effects improve endothelial function and increase nitric oxide production [54] , therefore producing a protective vasodilatatory effect. Furthermore, Delerive et al. [55] have demonstrated that aortas from PPAR null mice display an exacerbated inflammatory response to lipopolysaccharide (LPS) stimulation demonstrating that the antiinflammatory activity of PPAR agonists requires the nuclear receptor expression in vivo. On the other hand, PPAR agonist treatment increased LPS-induced plasma tumor necrosis factor (TNF ), a proinflammatory agent. Such effect was significantly decreased in PPAR null mice [56] , suggesting a proinflammatory role of PPAR . In contrast, Poynter et al. have shown that splenocytes from PPAR null mice produce higher levels of IL-6, supporting a PPAR -dependent antiinflammatory action [57] . Matrix metalloproteinase 9 (MMP-9) [58] and TF [53] are macrophage proteins that promote lesion instability and coagulation, respectively. In vitro, PPAR agonists inhibit the expression of these proteins in macrophages, thereby providing a possible mechanism by which PPAR agonists might stabilize atheromas and reduce thrombogenesis. The molecular mechanisms explaining the interaction of PPAR at several levels of inflammatory signalling pathway have recently been reviewed [59] .
Since PPAR is highly expressed in liver, a role of PPAR in regulating inflammatory response at the hepatic level was expected [59] . The acute phase response is an important inflammatory process for the initiation of defense mechanisms, but may become deleterious if chronic activation is reached. IL-6 and IL-1 stimulate the production of acute-phase proteins such as C-reactive protein (CRP), fibrinogen, and serum amyloid A (SAA), which are markers of cardiovascular disease. Fibrates are shown to be negative regulators of all these positive acute-phase proteins ( Fig.  (1B) ) [60] and others [61] . Interference of PPAR with the C/EBP signalling pathway has been suggested as the molecular basis for the inhibition of IL-6 induced fibrinogenand and of SAA expression [19] . A similar mechanism which interferes with the NF-B signalling, has been described for the fibrate-mediated inhibition of IL-1 induced expression of CRP [62] . Therefore, expression of acutephase proteins is downregulated by PPAR activators, and their plasma levels are lowered after fibrate treatment in humans. In fact, fenofibrate treatment of dyslipidemic patients decreases the plasma concentrations of fibrinogen, SAA, IL-6, and CRP, whereas levels of albumin, a negative acute phase response protein, are augmented [63] .
MECHANISMS CONTROLLING PPAR ACTIVA-TION (AND AFFECTING ITS EFFECTIVENESS)
There are several factors which may modulate PPAR activity: its cellular content, the nature of ligand, the crosstalk signalling and the structure of the PPRE ( Table 1 ). In addition, posttranslational modifications are important regulatory controls: phosphorylation, sumoylation and ubiquitination, among others [14] . Those factors modulating PPAR agonists response might be responsible for the variable, sometimes inefficient, drug-induced hypolipidemic action, and the mixed results yielded in clinical cardiovascular trials (Table (1)) [64] .
RELATIVE CELLULAR CONTENT OF PPAR
To date, there has been very little research related to the regulation of PPAR expression. Studies have reported that the regulation of PPAR expression is carried out either by glucocorticoids [65] , insulin or, even by fatty acids and fibrates [66, 67] . PPAR mRNA and protein levels change in parallel with the circadian rhythm of circulating glucocorticoids. Stress or fasting, which induce an increase in the level of plasma glucocorticoids, also result in enhanced synthesis of PPAR [65] . Although conflicting results regarding the regulation of PPAR expression by insulin exist [68, 69] , it seems that the down-regulatory effect of insulin is only observed when the expression of PPAR is already augmented. This counterregulatory effect of insulin has been described both in vitro by Steineger et al. [69] and in vivo by us [66] . Our studies in vivo in rat during perinatal development showed that PPAR mRNA and protein levels varied profoundly, reaching a high value during the suckling period and later declining in adult rats [70] . This difference was clearly related to both the milk intake, rich in lipids, and the low insulinemia [66] . In fact, it was observed that an oral load of fat was able to markedly increase hepatic PPAR expression, unless plasma insulin levels were high [66] . Moreover, an upregulation of PPAR gene expression by its own ligands, fibrates or FFA, which would suggest an autoregulatory feedback loop of this nuclear receptor ( Fig. (2) ), has been found both in rat cells [68] and in vivo studies in adult rat liver [67] , and confirmed in PPAR null mice [71] .
More specifically, the nuclear content of PPAR will be a determinant in its capacity for gene expression regulation. The unbound form of PPAR is generally present in cytosol, in a complex with a cytoplasmic chaperone. After binding an agonist, the complex is dissociated and PPAR migrates to the nucleus (Fig. (2) ) [72] . In fact, it has been shown that PPARs are able to bind with both heat shock protein (hsp) 72-kDa [73] and hsp90 [74] .
A better understanding of how PPAR expression is regulated is important since PPAR protein levels determine the response to PPAR agonists. Duez et al. [75] , using human apo A-I transgenic mice on a PPAR +/-background, demonstrated that the fibrates were less effective in reducing plasma lipids and modulating liver mRNA levels than in human apo A-I PPAR +/+. These findings showed that PPAR is required for the response to fibrates in a gene dosage-dependent manner [75] . Another situation where PPAR expression levels might mediate different responses to PPAR agonists in gene expression is in ageing. Old rats show a profound reduction in the expression and activity of hepatic PPAR [76] . They are resistant to the hypotriacylglycerolemic effect and to increasing the liver expression of PPAR target genes when treated with either gemfibrozil or bezafibrate at doses that are effective in young animals [64] .
Possibly related to that, negative results were found in several clinical trials with fibrates, the population over 65 years of age being the one unresponsive to fibrate administration [64] . In fact, a common observation in fibrate-treated patients is the considerable variation in induced lipid changes.
It has been reported that human liver PPAR mRNA levels vary >2-fold among individuals, therefore it is likely that in humans, the response to fibrate treatment differs between individuals because of differences in PPAR expression levels [75] . Moreover, in a 3 year study with fenofibrate, patients were divided into high responders and low responders in their plasma TG. In the high responders group, there was a prevalence of PPAR intron 7 GG homozygotes when compared to the low responders [77] . The mechanisms by which the intron 7 variant influences the TG reduction in response to fenofibrate treatment are unknown. There are many examples of regulatory regions being situated in introns, and therefore affecting the expression of the mRNA and the protein levels. However, it is unlikely that the intron 7 variant is itself functional as it is not close to the splice branch point sequence [77] . Whether the G/C intron 7 polymorphism is directly involved in the genetic control of PPAR level remains to be elucidated.
Interestingly, the Holden and Tugwood hypothesis [78] has also speculated that relative amounts of PPAR might mediate different responses in gene expression. Thus, the expression of peroxisome proliferation genes (i.e. ACO, PPAR itself) would be sensitive to PPAR ligands when a high level of PPAR is present. However, the expression of genes related to lipid and/or carbohydrate metabolism (i.e. PEPCK, LPL) would be responsive to activators even when the PPAR amount was low. Such explanation would justify the different sensitivity of PPAR gene expression to nutritional changes found by us in the liver of suckling rats (displaying a high PPAR level) and adult rats (having a low PPAR level) [47] . Moreover, it has been suggested that the low levels of PPAR expression in human liver, compared to mouse liver, may be responsible for human unresponsiveness to peroxisome proliferation [79] . In humans, the low amount of PPAR would be limiting and only the genes related to hypolipidemia may be induced upon exposure to ligand. In rodents, the high level of PPAR would be sufficient to activate both the genes associated to lipid metabolism and the genes related to peroxisome proliferation. In fact, in rodents, the peroxisomal ß-oxidation pathway is much more induced than the mitochondrial ß-oxidation pathway by PPAR agonists treatment. On the contrary, in man, the mitochondrial ß-oxidation pathway is strongly induced, but the peroxisomal ß-oxidation is not [80] .
NATURE OF THE LIGAND
Data relied on in vitro assays with direct addition of fatty acids at high concentrations showed that a wide variety of saturated and unsaturated fatty acids bind to PPAR , but with relatively low affinity. Nevertheless, it seems that circulating diet-induced changes in blood levels of unsaturated fatty acids are sufficient to slightly modify PPAR activity [14] . Due to the relatively high concentration of endogenous ligands present within the cell, it is difficult to establish which molecule is the true endogenous physiologic PPAR ligand [4] . Therefore, an alternative strategy has been to evaluate enzymatic pathways that could locally generate ligands. Thus, it was demonstrated that LPL releases fatty acids from TG-rich lipoproteins that activate PPAR in ECs, although other lipases equally effective at generating FFA were unable to activate PPAR [52] , suggesting differences in the intracellular localization of those FFA or a selective regulation of the receptor. In this same sense, it has been shown that de novo synthesized fatty acids regulate PPAR activity, whereas the fatty acids released from adipocytes are less active [81] . One possibility is that lipid binding proteins select the fatty acids to be shuttled to PPAR [82] . The role of FABP and other cytoplasmic transporter proteins guiding the ligands to the nuclear receptors and mediating in the interaction of PPAR with its agonists has been suggested [82] [83] [84] and already confirmed, at least, for retinoic acid.
In a way similar to that shown for natural ligands, fibrates that are low affinity ligands for PPAR , must generally be used at high doses to achieve efficacious lipidlowering activity [85] . Moreover, fibrates appear to act preferentially in the liver, whereas high-affinity ligands, such as Wy-14,643, are suspected of acting more efficiently in peripheral tissues [4] , indicating tissue specificity in the response to PPAR activation [86] . Moreover, different fibrates may have different, and even opposite, effects. In one old study, it was observed that in animals receiving a standard diet, fenofibrate and gemfibrozil decreased the TG level, whereas in animals receiving a hypercholesterolemic diet, fenofibrate, but not gemfibrozil, lowered plasma TG [87] . A similar situation was found in animals fed a hypertriacylglycerolemic diet, where the diminution in plasma TG levels provoked by fenofibrate was not observed with gemfibrozil [87] . In a study using bezafibrate and gemfibrozil, both drugs lowered plasma TG to about the same extent in both chow-fed and hypertriacylglycerolemic rats. However, gemfibrozil lowered LDL-cholesterol and elevated HDLcholesterol, whereas bezafibrate produced the opposite effects [88] . Furthermore, changes in liver TG concentrations in hypertriacylglycerolemic rats produced by these drugs were opposing [88] .
To increase the complexity, species differences in ligand activation of PPAR cannot be discarded. For example, fibrates are more effective than linoleic acid in promoting PPAR activation in cultured rat hepatoma cells, whereas linoleic acid is more effective than fibrates in human hepatoma cells [89] . Furthermore, it has been suggested that alteration of gene transcription by fatty acids and fibrates is often disconnected in different target genes. Accordingly, it has been suggested that not all of the fatty acid effects can be assigned to PPAR activation [48] . For example, in hepatocytes, lipoxygenase inhibitors impair activation of CPT-I gene expression by fibrates, but do not affect the induction by fatty acids. Peroxisome proliferators, but not long-chain fatty acids, induce CPT-II in fetal rat hepatocytes ( Fig. (2) ). The enzyme stearoyl-CoA desaturase 1 (SCD1), which catalyzes 9 desaturation of saturated fatty acids, is upregulated by fibrates but downregulated by PUFA ( Fig. (2) ) [48 and references therein].
Interestingly, fatty acids can displace high-potency synthetic PPAR ligands from expressed PPAR protein in cell-free assays [52] . In fact, long-chain fatty acids can also compete or displace peroxisome proliferators for binding to FABP [83] , which would be influenced by the relative intracellular concentration of both agonists. Possibly, such competition between fibrates and FFA would make the regulation of both overlapping and different sets of genes possible, resulting in specific and common biological responses [21, 67] . Therefore, FFA could decrease the availability of the fibrates to their corresponding PPAR site, substantially reducing the capability of fibrates to activate PPAR and, consequently, its metabolic effects. This fact could explain those studies describing fibrates failing, or not sufficiently correcting, hypertriacylglycerolemia under certain conditions. That would be the case of animals receiving a high-fat diet along with fibrate [86] . In our hands, in late pregnant rats whose FFA levels are high, fenofibrate was ineffective in reducing their hypertriacylglycerolemia. In pregnant rats the triacylglycerolemia increases over time. Thus, although plasma TG decreased during the first 2 days of fenofibrate treatment in pregnant rats, the effect disappeared on day 3, and plasma TG were even enhanced on day 4. On the contrary, in nonpregnant rats, fenofibrate decreased plasma TG throughout the experiment [21] . In a similar experiment, short-term treatment with fenofibrate to hypertriacylglycerolemic Zucker obese rats markedly raised TG in comparison to untreated obese control rats [90] . Another study showed how in fatty Zucker non-treated rats, plasma TG had increased after 4 weeks in comparison to the initial day of the experiment. Interestingly, semichronic treatment with fenofibrate was only able to prevent the increase in TG observed in control Zucker rats, whereas rosiglitazone, a PPAR ligand, was able to reduce the hypertriacylglycerolemia efficiently [91] . Related to the competition between fibrates and FFA to activate PPAR , subjects affected by massive hypertriacylglycerolemia have turned out to be hyporesponsive to fibrates. Curiously, coenzyme Q10 improved the efficacy of fenofibrate in massive hypertriacylglycerolemia patients not responding to fenofibrate alone, possibly as a result of a direct effect on mitochondria to increase fatty acid oxidation with a consequent reduction of circulating FFA levels [92] .
A permanent elevation of plasma FFA is the dominating factor in obese related metabolic syndrome. According to the original hypothesis of Randle et al. [93] , increased fatty acid availability competitively inhibits glucose oxidation in the muscle, inducing a diminution of glucose uptake and insulin resistance. PPAR activation favors fatty acid oxidation and is one of the reasons why fibrates have lipid-lowering effects and why PPAR ligands could, in some situations, improve insulin sensitivity by reducing lipid accumulation in tissues [94] . However, only a few clinical trials have reported an improvement of glucose homeostasis after fibrate treatment [95, 96] . Furthermore, these beneficial effects of fibrates on glucose control may not be attributable alone to enhanced fatty acid oxidation related to PPAR activation, because some of those compounds have also modest PPAR activity [97] . Thus, the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study did not reveal any fenofibrate effect on glucose parameters in diabetic patients [98] , and a recent report concluded that administration of fenofibrate for 3 months did not affect insulin sensitivity in obese subjects with type 2 diabetes [99] .
CROSS-TALK SIGNALLING AND STRUCTURE OF PPRE
DR-1 elements present in PPRE are also recognized by other nuclear receptors such as RAR:RXR, RXR homodimers, HNF-4 and chicken ovalbumin upstream promotertranscription factor (COUP-TF). In fact, HNF-4 and COUP-TF homodimers can displace PPAR:RXR from its binding site and thus compete with PPAR signalling [100, 101] . The effectiveness of these interactions depends on the sequence of the regulatory element and the context of the promoter, suggesting cross-talk with other nuclear receptors that may generate different agonistic/antagonistic actions and influence metabolic control [4, 102] . Moreover, on the one hand, RXR is the indispensable dimerization partner of the PPAR and other nuclear receptors such as RAR, thyroid hormone receptor, and vitamin D receptor; and on the other hand, as commented above, there are multiple types of cofactor proteins (coactivators and/or corepressors) which are recruited by many different nuclear receptors, PPAR included, in order to assemble the transcriptional machinery at the target gene promoter [16] . Thus, a competition between nuclear receptors exists. Differences in both the expression of these factors and cofactors and the interactions of one or several of these proteins upon addition of ligands could modulate the capacity of PPAR to regulate the expression of target genes. This might explain the differences found in the response to PPAR agonists interspecies or between diverse cell types [72] .
For example, in the human apoA-II transgenic mice, which share some similar phenotypic characteristics with PPAR null mice, fibrate-induced PPAR activation did not correct the combined hyperlipidemia. Thus, after two weeks of treatment with fenofibrate, human apoA-II transgenic mice presented an unexpected increase in plasma TG, mainly due to an impaired VLDL catabolism and PPAR signalling [103] . As PPAR liver gene expression was demonstrated, its functional impairment could result from a defective recruitment of the coactivators that modulate its activity on several critical gene targets. On the other hand, several mechanisms have been suggested to explain the effects of PPAR activation on apo C-III gene regulation: first, a competition between PPAR and HNF-4 for binding to the apo C-III promoter and a substitution of the strong activator HNF-4 by a less active PPAR:RXR complex may explain a reduction of apo C-III expression which depends on the relative abundance of PPAR and HNF-4. Second, apo C-III repression by fibrates might occur via PPAR -dependent enhanced expression of a negative regulator of transcription. Thus, PPAR activators induce the hepatic expression of Reverb , a nuclear orphan receptor which is a strong repressor of transcription [104, 105] . Third, PPAR might repress transcription of apo C-III by physically interacting with other transcription factors, leading to the formation of inactive complexes and thereby limiting the induction of apo C-III expression. This seems to be the case for the positive transcription factor forkhead box O1 (FoxO1) [106] .
Moreover, competition is thought to occur among PPAR isotypes [107] . The subtype ß of PPAR has been reported as a physiological human antagonist of PPAR [107] , and therefore, a higher expression of the PPARß isoform in human cells than in cells of rodent origin could imply an impairment of PPAR activity in human cells [72] . However, other authors have proposed that the functions of PPARs and may be redundant as transcriptional regulators and have even suggested that the beta-subtype might compensate for deficiency of PPAR [108] . In a similar way, PPAR function could be antagonized by dimerization of the orphan LXR with either PPAR or RXR , leading to a complex that cannot bind to DNA responsive elements [80] . In addition, the PPAR:RXR complex also recognizes an estrogen response element (ERE) [109] . The possibility of a hormonal cross-talk through ERE exists [109] and genes might be found to be coregulated in an opposite manner by the estrogen receptor (ER) and PPAR:RXR. Thus, for example, mixed studies carried out either in wild-type, LDL receptor-deficient or ovariectomized mice have suggested the involvement of estrogen in the regulation of obesity and hypertriacylglycerolemia by fenofibrate [110] . In a recent study with ovariectomized mice, the concomitant treatment with fenofibrate and estradiol showed that the hormone reversed the effects of fibrate on plasma lipids and hepatic PPAR target gene expression [111] . Related to that, in late pregnant rats treated with fenofibrate, there may be a competition between fenofibrate and estradiol, whose levels during late pregnancy are extremely high [112] , to be the "conductor" of the lipid metabolism [67, 113] . Furthermore, a marked dichotomy in the response to atorvastatin, a hypolipidemic statin known to induce the hepatic expression of PPAR in rats [114] , was found between old male and female rats. Senescent females were practically resistant to the effects of atorvastatin on lipid metabolism, probably as a result of the inhibitory activity of high estrogen levels on PPAR transactivating activity [115] .
On the other hand, human primary hepatocytes treated with Wy-14,643 or fenofibrate displayed a strong induction of apo A-V mRNA [102] through activation of PPAR and binding to a functional PPRE. These findings demonstrate that apo A-V is a highly responsive PPAR gene in humans [102] . However, a PPRE has not yet been identified in the rat apo A-V promoter, probably indicating an additional interspecies difference [116] . This is similar to what occurs with the apo A-I, one of the major protein constituents of HDL. The human apo A-I gene contains functional PPRE, whereas it is not functional in rodents due to a difference in three nucleotides between rodent and human PPRE, which prevent PPAR binding to the rodent PPRE [105] . Activation of PPAR by fibrates induces human apo A-I expression, increasing HDL, whereas in rats fibrates suppress apo A-I expression and decrease HDL levels (Fig. (2) ) [80] . In rodents, Rev-erb binds to a negative response element adjacent to the TATA box, present only in the rat apo A-I promoter [105] . Since fibrates induce Rev-erb expression [104] , rodent apo A-I expression may be repressed via this mechanism.
Sometimes, the difference is not in the structure of the PPRE but in the conformation of the PPAR DNA-binding domain (DBD). For example, PPAR null mice expressing human PPAR in their livers functionally responded to Wy-14,643 and fenofibrate in a manner similar to wild-type mice, by controlling the expression of known target genes [117] . However, mice having human PPAR did not exhibit peroxisomal proliferation nor hepatocarcinoma, which was observed in mice having murine PPAR , despite the fact that the expression levels of PPAR were comparable in both types of mouse [117] . Human and rat PPAR are not exactly identical in their DNA-and ligand-binding domains and it has even been reported that a single amino acid change in some of these domains of PPAR profoundly alters its transcriptional activity [118] . Related to that, polymorphisms in the PPAR gene may also contribute to the different responses to fibrate treatment. In fact, a significant genotypedependent response to gemfibrozil [119] , as well as to fenofibrate [120] , treatment in lipidemia with the PPAR Leu162Val polymorphism has been found. This leucine to valine (Leu162Val) substitution at the PPAR gene is functional and affects ligand-transactivation activity of PPAR . The Leu162Val polymorphism affects the DBD of the receptor, and therefore this mutant receptor may not bind to PPREs as efficiently as the wild-type receptor. However, in this mutant form of the receptor, the low activation found with low doses of ligand is overcome at high doses [121] .
Altogether these factors modulating PPAR agonists response would perhaps explain the mixed results yielded by prospective clinical cardiovascular trials with these agents. In some clinical trials with cardiovascular endpoints, fibrates have yielded either beneficial effects restricted to some types of patients or even negative outcomes [recently reviewed by Sanguino, 2007] [64] . Thus, in the Helsinki Heart Study (HHS), cardiovascular disease risk reduction upon gemfibrozil treatment was most pronounced in obese patients with metabolic syndrome or diabetes and atherogenic dyslipidemia [63] . In the Bezafibrate Infarction Prevention (BIP) trial, reduction in coronary events with bezafibrate was observed only in patients with elevated serum TG concentrations. In the Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial (VA-HIT), the significant beneficial effects of gemfibrozil were shown in diabetics or in nondiabetics with high insulin levels [4] . Furthermore, in the FIELD study, although fenofibrate lowered TG as well as LDL cholesterol and hardly elevated HDL cholesterol, it did not reduce the risk of coronary events. Actually, due to the heterogeneity of the study subjects, many of those conclusions were obtained by analyzing results from a special subgroup of the study population of patients [64] . In other cases, the interpretation of the study was complicated by concomitant drug use; for example, in the FIELD study, the use of statins throughout the study in both groups (placebo and fenofibrate) [63] . As commented above, the influence of the ageing process in the manifestation of fibrates effects cannot be discarded. The analysis a posteriori of data from FIELD and Low Extremity Arterial Disease Event Lowering in Diabetes (LEADER) studies show a marked reduction in cardiovascular events in the patient population younger than 65 years, indicating that the population older than 65 years was the one unresponsive to fibrate administration, and the one responsible for the negative outcome of these assays [64] . Perhaps, similar conclusions could be obtained if the association between PPAR gene variants and response to fibrate treatment was examined in those studies. For example, in the St. Mary's, Ealing, Northwick Park Diabetes Cardiovascular Disease Prevention (SENDCAP) study, a greater reduction of total cholesterol in response to bezafibrate treatment was observed in the PPAR Val162 allele carriers than in the Leu162 carriers [77] . Moreover, the association between PPAR Leu162Val polymorphism and the risk of a cardiovascular event, as well as response to gemfibrozil therapy was greatest in those patients with either insulin resistance or diabetes mellitus in VA-HIT [122] . Besides, the older fibrates (gemfibrozil and bezafibrate) used in the previous studies are less specific for PPAR than fenofibrate and so may be acting, at least in part, through PPAR and/or PPAR [77] . Finally, it seems to be that compounds related to the -carotene could inhibit the activation of PPAR by their agonists [52] . As already noted, coenzyme Q10 also affects the effectiveness of fenofibrate in correcting dyslipidemia [92] . Therefore, the results of clinical trials with fibrates might be affected by the supplementation used:carotene, coenzyme Q10, and so on.
PHOSPHORYLATION AND OTHER POSTTRANS-LATIONAL MODIFICATIONS
The phosphorylation-dephosphorylation process is an important regulatory mechanism of transcriptional activity of nuclear receptors. In fact, PPAR is a phosphoprotein and its function is affected by cross-talk with kinases and phosphatases [123] . Therefore, PPAR activity is dependent on its phosphorylated state [124] . Thus, it is possible that the activation by ligand-independent mechanisms of PPAR is associated with kinase-dependent processes [123] . Activators of protein kinase A can increase PPAR activity in the absence and the presence of receptor agonists [123] . Nevertheless, it has been observed that the phosphorylation of PPAR may be enhanced by treatment with peroxisome proliferators like ciprofibrate. In addition, cell treatment with phosphatase inhibitors decreases the levels of ciprofibrate-induced gene expression [124] . Insulin also increases the phosphorylation of PPAR , enhancing its transcriptional activity [125] . On the other hand, PPAR activity has also been shown to be modulated by mitogen-activated protein kinase (MAPK). Thus, the inhibition of MAPK reduces PPAR activity [123] . Further, inhibitors of HMG-CoA reductase, such as cerivastatin, acting through the prenylation of Rho A small G protein, can regulate MAPK signalling which, in turn, modulates the PPAR transcriptional activity [126] . This is an important cross-talking between fibrates and statins [123] . Eventually, modification of the phosphorylation state of PPAR affects ligand affinity [80] .
PHARMACOLOGICAL AND NATURAL ACTIVA-TORS OF PPAR
Metabolic syndrome, type 2 diabetes mellitus and dyslipidemia are increasing worldwide. However, many of these patients are not receiving appropriate treatment [127, 128] . Generally, fibrates, PPAR agonists, have been accepted as the most promising treatment. However, as already commented, a number of animal and human studies have revealed potential adverse effects or failure of PPAR activation by fibrates, underlining the need to search for alternative or complementary therapies [52] ( [129, 130] for a review). Furthermore, fibrates are weak agonists of PPAR , and high doses are required for effective treatment [85] . In addition, selective PPAR agonists with higher potency and specificity are supposed to display greater effectiveness and fewer adverse effects. These alternative therapies are currently being developed and proving useful [14, 129, 131] . In this article, we briefly review of the most noticeable agents ( Table 2) .
On the other hand, whichever PPAR therapeutics is used, it should be based on a better understanding of PPAR biology, the nature of endogenous PPAR agonists, and how these molecules are generated. Moreover, these PPAR agonists-producing pathways, when defective, might generate inadequate PPAR ligands which may contribute to pathological situations [52] . Whether this should be the case, an alternative strategy would be either to promote the production of the "appropriate" endogenous PPAR agonists or the design of agents which might compete with and displace the "inadequate" PPAR ligands for binding to PPAR. A similar behaviour has been suggested for the PPAR agonists, TZDs [129, 132] .
DUAL PPAR / AGONISTS, DUAL PPAR / AGO-NISTS AND PAN-AGONISTS
Glitazars are dual PPAR /PPAR agonists that are being studied in the treatment of diabetes and metabolic syndrome. Among others, there are naveglitazar, muraglitazar, ragaglitazar, tesaglitazar, and chiglitazar [133] . All of them reduce TG and raise HDL levels and improve insulin sensitivity. Besides, ragaglitazar, tesaglitazar and muraglitazar improve fatty acid and lipoprotein metabolism by decreasing apo B and apo C-III plasma levels and inducing activity of hepatic LPL and CPT-I [131] . In addition, treatment with ragaglitazar significantly reduced blood pressure in spontaneous hypertensive rats and improved endothelial function in Zucker fatty rats when compared with pioglitazone treatment [134] . Due to excellent findings in animal models, clinical trials in humans were initiated. A phase III clinical trial with type 2 diabetic patients compared treatment with muraglitazar versus pioglitazone, both in combination with metformin [135] . Muraglitazar plus metformin showed significantly greater improvement in glycemic control, reduction in plasma TG and an increment in plasma HDL than pioglitazone plus metformin. However, it was also found that death, non-fatal myocardial infarction, or stroke occurred in a higher number of patients treated with muraglitazar, as compared to patients treated with pioglitazone or placebo. Therefore, the clinical study with muraglitazar was recently discontinued due to higher incidence of edema and heart failure [136] . Further-more, in clinical trials, tesaglitazar was shown to elevate blood creatinine levels in patients, indicating potential kidney toxicity. Therefore, these two promising compounds were discontinued in May 2006, and at present, new molecules are being tested [136] . In the same sense, although ragaglitazar showed an excellent profile in clinical trials, due to some incidence of bladder tumor in rodents, the trials have been discontinued [133] .
On the other hand, DRF 2519, an analogue of the TZDs, has also shown dual activation of PPAR and . In an insulin-resistant ob/ob mouse model, DRF 2519 showed better alleviation of insulin resistance and dyslipidemia than rosiglitazone. In fatty Zucker rats, DRF 2519 showed greater reduction in plasma insulin, TG and FFA levels and enhanced aortic smooth muscle relaxation than rosiglitazone [137] . In high-fat fed Sprague Dawley rats, DRF 2519 improved plasma lipid profiles more than fenofibrate or rosiglitazone. These results indicate that DRF 2519 could be an interesting candidate in the management of metabolic disorders and associated complications [137] . Another novel PPAR /PPAR dual agonist is LSN862, which shows improvements in glucose and lipid levels in rodent models of type 2 diabetes and dyslipidemia. In Zucker diabetic fatty rats, LSN862 showed a higher glucose and TG lowering activity than rosiglitazone. In addition, LSN862 in db/db mice demonstrated better antidiabetic efficacy compared with rosiglitazone. In the humanized apo A-I transgenic mouse, LSN862 and fenofibrate reduced VLDL levels, whereas rosiglitazone increased them [138] . Recently, T659, a PPAR / dual agonist was shown to increase HDL levels in primates [139] . This is interesting as there are very few therapeutic drugs available to increase HDL-cholesterol (HDL-C) concentrations in dyslipidemic patients, since fibrates cause slight increases in HDL-C concentration, and TZDs, like statins, have little or no effect on HDL-C.
The most well-known pan ( , and )-PPAR activator is bezafibrate, with more than a quarter of a century of safe therapeutic use. Bezafibrate improves both insulin sensitivity and blood lipid profile in patients with metabolic syndrome [140] . Therefore, bezafibrate-based clinical studies support the use of pan-PPAR ligands as therapeutic agents against the metabolic syndrome. Nevertheless, since bezafibrate is a weak PPAR ligand, more powerful new pan-PPAR compounds should be developed for the treatment of diseases in which lipid and glucose metabolism disorders coexist. Thus, novel PPAR pan-agonists such as netoglitazone and PLX 204 are under investigation. In the near future, they may be potent therapeutic agents used in the treatment of diabetes associated with cardiovascular complications [133] . In fact PPAR pan-agonists have displayed antidiabetic actions without the usual weight gain associated with PPAR agonists [133] . Thus, netoglitazone has been shown to decrease plasma fatty acid, glucose, and TG levels and increase insulin sensitivity in obese and diabetic rats [141] . Nevertheless, given the multiple sites of action of PPAR pan-agonists, which involve the transcription of a vast array of genes, more information regarding toxicity in humans is required [133] .
SELECTIVE PPAR MODULATORS (SPPARMS) AND PARTIAL AGONISTS
The concept of Selective PPAR Modulators (SPPARMs) was suggested by analogy to Selective Estrogen Receptor Modulators (SERM), which proposes that each different ligand can have different agonist or antagonist properties depending on the cell context and the specific target gene in question. PPAR ligands with different chemical structures 
Classes of Drugs and/or Nutrients Examples of Natural and Synthetic Agonists
Dual PPPAR / Agonists • Naveglitazar, muraglitazar, ragaglitazar, tesaglitazar, and chiglitazar [131, [133] [134] [135] [136] .
• DRF 2519 [137] .
• LSN862 [138] .
Dual PPAR / Agonists • T659 [139] .
Pan-agonists • Netoglitazone and PLX 204 [133, 141] .
Selective PPAR Modulators (SPPARMS)
• Metaglidasen [133] .
• FK614 [143] .
Nutraceuticals
• Omega-3 fatty acids [145] .
• Conjugated linoleic acid (CLA) [146, 147] .
• Fatty acids with ethanolamine (FAE) [148] [149] [150] .
• Antioxidant therapy, such as vitamin E [57, 80] .
• Isohumulones [151, 152] .
• Genistein, daidzein and other soy isoflavones [153] [154] [155] .
• Beta-carotene [52] .
• Pterostilbene, piceatannol and resveratrol [156] .
(SPPARMs) bind to the LBD of the receptor, inducing distinct conformational changes that lead to different binding affinities for the various cofactors and, thus, activate PPAR in distinct ways provoking differential gene expression and biological responses. Nevertheless, it should be kept in mind that, unlike classical steroid hormone receptors, PPAR receptors have a large ligand-binding pocket which is not fully filled with the ligand [142] . Thus, the working hypothesis is that the best therapeutic strategy is to select a desired PPARmediated action in one cell type without inducing an adverse PPAR-mediated effect in another [80] . The greater part of SPPARMs that have been developed to date act on PPAR , and have been shown to selectively modify gene expression and reduce insulin resistance without causing weight gain [133] . Thus, metaglidasen decreased insulin and glucose concentrations, increased adiponectin concentrations, and improved plasma lipid profile without causing weight gain in diabetic mice [133] . A SPPARM with differential properties in the regulation of fat cell function is FK614. This compound behaves as a partial agonist in inducing the interaction of PPAR with both transcriptional coactivators CBP and SRC-1, but as a full agonist with both PBP and PRIP, which are required for PPAR -mediated adipogenesis. Therefore, in differentiating 3T3-L1 adipocytes, but not in mature adipocytes, FK614 induces adipocyte fatty acid-binding protein (aP2) mRNA expression and TG accumulation, whereas TZDs produce the same effects at the two stages of adipocyte differentiation. Since FK614 behaves as SPPARM with stage-dependent selectivity, it may contribute to ameliorate insulin resistance without stimulating fat accumulation in adipocytes [143] . On the other hand, gemfibrozil, a clasical PPAR agonist, has recently been considered a SPPARM [75] . Accordingly, gemfibrozil is structurally unique as compared with other fibrates. Thus, whereas fenofibrate behaves as a full agonist, gemfibrozil appears to act as a selective modulator of PPAR , due to a differential recruitment of coactivators to the PPAR :RXR-DNA complex [75] . Such distintive interaction between PPAR and its cofactors may transmit signals that result in a unique gene regulatory activity [85] . These observations would explain the differences found between fenofibrate and gemfibrozil in the apoA-I expression and plasma levels [75] .
Interestingly, Feige et al. [144] have clearly established the difference between selective PPAR modulators and partial PPAR agonists, two terms that are very often interchangeable [75, 133] . SPPARMs induce conformational changes different from full agonists, which produce a selective induction of corregulator recruitment, target gene induction, and physiological effects. Indeed, SPPARMs differ from partial agonists, as they promote selective gene regulation by differentially affecting target gene transcription in a gene-specific manner. Thus, some genes are induced to similar levels than those obtained with a full agonist, whereas others exhibit restricted activation. In contrast, when compared with full agonists, partial agonists exhibit a global decrease in the activation of all target genes [144] .
NUTRACEUTICAL APPROACHES
We should remember that circulating diet-induced changes in blood levels of PUFA are sufficient to modestly modify PPAR activity [14] . Moreover, natural ligands of PPAR such as eicosapentaenoic acid and docosahexanoic acid are often found in over-the-counter fish oil or -3 supplements [133] . Interestingly, PUFA, especially those of the -3 class, are known to affect all the metabolic nuclear receptors that modulate TG levels, LXR and HNF-4 , as well as the three PPARs [145] . In fact, the efficient hypotriacylglycerolemic effect of -3 fatty acids has been explained by their coordinated action on these different nuclear receptors.
Conjugated linoleic acid (CLA) is found naturally in animal tissues and food sources. Although the action mechanism(s) of CLA is/are not clearly understood, it has been proposed that activation of PPAR and/or PPAR may account, in part, for the beneficial effects of CLA on atherogenesis, diabetes and immune function, as reported in animal studies [146, 147] .
Amides of fatty acids with ethanolamine (FAE) are produced naturally in mammalian cells through the concerted action of two enzymes. FAE are a family of natural active lipid mediators, present in circulating blood and tissues, which participate in a variety of biological functions including the regulation of feeding [148] and improvement of myocardial function in conditions of cardiomyopathy [149] . The monounsaturated FAE oleylethanolamide (OEA) stimulates both adipose tissue lipolytic activity and hepatic fatty acid oxidation through the activation of PPAR [150] .
Reductions in PPAR gene expression might contribute to the pro-oxidant state observed in aged animals, possibly due to a deficiency in the modulation of the cellular redox state. Aged mice have been shown to express reduced mRNA levels of PPAR and target genes, such as peroxisomal ACO. Reciprocally, that pro-oxidant state may be a cause of the reduced expression of PPAR found in old rats [76] . Interestingly, supplementation of old mice with vitamin E caused elevations in PPAR and ACO transcripts to the levels seen in young animals [57] , suggesting that balancing the cellular redox state may positively affect the transcriptional regulation of the PPAR gene. Moreover, since some of the adverse effects of PPAR action appear to be due to the compounds generated in oxidized fatty-acid metabolism, co-administration of a antioxidant therapy, such as vitamin E, with PPAR ligands might alleviate or prevent the undesirable effects of PPAR agonists [80] .
There have been few studies concerning the biological activities of the isohumulones found in beer, but some of them have reported that isohumulones can activate PPAR and PPAR [151] . It has been proposed that isohumulones improve insulin resistance in diabetic mice [151] through their effect of enhancing PPAR expression, It has also been proposed that isohumulones raise plasma HDL-cholesterol levels and reduce liver cholesterol and TG in mice, through their effect of enhancing PPAR expression [152] .
Substantial data from epidemiological and nutritional studies in humans and animals have indicated that soy protein intake reduces serum total and LDL cholesterol and TG as well as hepatic cholesterol and TG [153] . Soy protein is unique among the plant-based proteins because it is associated with isoflavones. Thus, Mezei et al., using PPAR null mice fed diets containing different levels of soy isoflavones, determined that significant improvements in serum TG levels are provided by the intake of soy isoflavones via both PPAR dependent and PPAR independent mechanisms [154] . Curiously, the chemical structure of isoflavones is similar to that of fibrates, and studies in vitro have demonstrated that soy isoflavones, particularly genistein and daidzein, are able to activate both PPAR and PPAR [154] . On the other hand, Mezei et al. showed that consumption of a high isoflavone soy protein diet improved glucose tolerance, insulin resistance, and hepatic cholesterol and TG concentrations in obese Zucker rats [155] .
The heterodimer composed of RXR and PPAR, can be activated by the RXR ligand 9-cis retinoic acid, independently of the presence or absence of a ligand for PPAR. Retinoic acid can be formed from the symmetric cleavage ofcarotene. Beta-carotene however, can also undergo asymmetric cleavage to yield a series of molecules known as apocarotenals. It has recently been hypothesized that apocarotenals, such as 9-cis retinoic acid, might also be transcription modulators. Thus, several studies have revealed that -apo-14' carotenal (apo14) is able to inhibit the activation of PPAR and RXR by their respective agonists. Possibly, apo14 might help to modulate the PPAR activation [52] .
Finally, polyphenolic compounds such as resveratrol, found in grapes, wine, and peanuts, have shown lipid and glucose lowering properties mediated by PPAR [156] . Rimando et al. investigated whether this compound and three analogues (pterostilbene, piceatannol and resveratrol trimethyl ether) would activate PPAR in vivo and in vitro. Pterostilbene demonstrated the highest induction of PPAR . Accordingly, in hypercholesterolemic hamsters, pterostilbene lowered plasma LDL cholesterol and glucose and increased plasma HDL cholesterol, as compared to the control group [156] . de Evaluación y Fomento de la Investigación (PI-06/0352) as well as the Fundación Universitaria San Pablo-CEU for financial support. The excellent technical assistance of Milagros Morante and the editorial help of Brian Crilly are greatly appreciated. 
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